Cystic Fibrosis-related DiabetesPhase 4NCT04533646
Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes
A Phase 4 study testing Insulin and Continuous glucose monitor (CGM) in people with Cystic Fibrosis-related Diabetes, run by Jagdeesh Ullal at 1 site in United States.
Trial summary
The aim of this study is to assess the utility of CGMs to determine the optimal method to dose meal-time insulin. The investigators will examine glucose excursions in patients with CF who will dose meal-time rapid-acting insulin by carbohydrate counting versus fixed-dose rapid-acting insulin. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Cystic Fibrosis-related Diabetes
- What is being tested?
- Insulin and Continuous glucose monitor (CGM)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Sep 2020to 1 Sep 2025
- Phase
- Phase 4
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age >18 age of years
- Diagnosis of cystic fibrosis related diabetes
- Using basal bolus insulin
- Cystic Fibrosis with Lung Transplantation
Who cannot join
- Use of continuous glucose monitors
- Patient unable to check fingerstick blood sugars
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Pittsburgh Medical Center, Center for Diabetes and Endocrinology
Pittsburgh, Pennsylvania, 15213
About this study
Official title: Comparison of Meal-Time Dosing of Rapid Acting Insulin Using Carbohydrate Counting vs. Fixed Doses Utilizing Continuous Glucose Monitoring In Patients With Cystic Fibrosis Related Diabetes
The aim of this study is to assess the utility of CGMs to determine the optimal method to dose meal-time insulin. The investigators will examine glucose excursions in patients with CF who will dose meal-time rapid-acting insulin by carbohydrate counting versus fixed-dose rapid-acting insulin. The carbohydrate ratio and fixed doses will be determined by existing doses, total daily insulin doses, body weight, and insulin sensitivity along with predisposition to hypoglycemia. Bolus insulin dosing is an important part of CFRD management due to the high nutritional demands of these patients. If dosed incorrectly, this could lead to marked hyperglycemia and could worsen nutritional status due to urinary glucose losses. In this project, the investigators will perform a within-subjects' comparison of the 2 standard methods of meal-time rapid-acting insulin dosing.
Read the detailed description
Background and Introduction Cystic fibrosis-related diabetes (CFRD) is the most common extra-pulmonary comorbidity in patients with cystic fibrosis (CF). CFRD is also associated with an accelerated decline in pulmonary function, increased pulmonary exacerbations, and increased mortality. Continuous glucose monitoring (CGM) involves the use of a small disposable sensor sited in the subcutaneous interstitial fluid that makes frequent glucose measurements. There is data suggesting that the Medtronic iPro continuous glucose monitors (CGM) can predict hemoglobin a1c levels in patients with CFRD.
The aim of this study is to assess the utility of CGMs to determine the optimal method to dose meal-time insulin. The investigators will examine glucose excursions in patients with CF who will dose meal-time rapid-acting insulin by carbohydrate counting versus fixed-dose rapid-acting insulin. The carbohydrate ratio and fixed doses will be determined by existing doses, total daily insulin doses, body weight, and insulin sensitivity along with predisposition to hypoglycemia. Bolus insulin dosing is an important part of CFRD management due to the high nutritional demands of these patients. If dosed incorrectly, this could lead to marked hyperglycemia and could worsen nutritional status due to urinary glucose losses. In this project, the investigators will perform a within-subjects' comparison of the 2 standard methods of meal-time rapid-acting insulin dosing.
Hypothesis:
- Postprandial interstitial fluid glucose levels in participants who utilize carbohydrate counting to dose mealtime rapid-acting insulin will have improved control as defined as the area under the curve and time in target compared to participants who used fixed-dose mealtime insulin
- Participants who utilize carbohydrate counting will have fewer hypoglycemia events compared to participants who use fixed-dose meal-time insulin
Specific Aims:
- To compare within-subject glucose excursions defined as the percentage of time in target glucose level, percentage of glucose in target, and peak postprandial glucose with fixed insulin dosing versus carbohydrate count based insulin dosing.
- To compare the frequency and duration of hypoglycemia (defined as the daily, weekly, and average duration of the event) between insulin delivery methods described above.
- To test the use of 'rule of 500' for carb counting estimation in patients with CFRD
- To compare the effect of two methods of rapid-acting insulin delivery on fasting glycemia
- Conditions
- Cystic Fibrosis-related Diabetes
- Being tested
- Insulin, Continuous glucose monitor (CGM)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InsulinDrug
Participants will be asked to dose insulin during the first week using fixed doses. During the second week of the study, participants will dose insulin based on carbohydrate counting. Blood sugar control will be compared between the 2 weeks to determine the outcomes of the study.
Continuous glucose monitor (CGM)Device
Participants will be required to wear a CGM to measure glucose trends
| Study group | Role | What they receive |
|---|---|---|
| Fixed Dosing, Followed by Carbohydrate Counting | Experimental | Dosing of premeal insulin with fixed doses Receives: Drug: Insulin; Device: Continuous glucose monitor (CGM) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time in Target
Measurement of percentage of time in target of glucose level
Measured: 2 weeks
Secondary outcomes (1)
Hypoglycemia
To determine the time spent in hypoglycemia as defined as blood sugar under 70 mg/dl
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2020
- Study start15 Sep 2020
- Primary completion31 Jul 2023
- Study completion1 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Cystic Fibrosis-related DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This study design involves a within-subjects comparison using a sequential cross over that occurs over a 2-week time frame. During the first seven days of wear, the participants will be asked to dose their mealtime rapid-acting insulin by fixed-dose, and the next seven days, participants will be asked to dose their mealtime rapid-acting insulin by carbohydrate counting. After the 14 days, participants will return their continuous glucose monitor (CGM) devices for analysis and interpretation.
- Masking
- None (open label)
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jagdeesh Ullal
- Sponsor type
- University, hospital or other
- Collaborators
- Wake Forest University Health Sciences
- Responsible party
- Sponsor-investigator, Jagdeesh Ullal, University of Pittsburgh
- Investigators
- Jagdeesh Ullal, MD, Principal investigator, University of Pittsburgh Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04533646
- Sponsor's protocol ID
- STUDY20060197
- Status last verified
- Oct 2025
- First submitted
- 23 Aug 2020
- Last updated
- 15 Oct 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No